Press Release

New therapeutic treatment being developed to reverse respiratory depression CHARLOTTESVILLE, VA., Sep. 27, 2023. Atelerix Life Sciences Inc., a leader in new therapeutics for unmet medical needs related to respiratory depression, announced today that it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for …

Atelerix Life Sciences Inc. Announces BARDA Contract to Support First-in-Human Clinical Trial of ATLX-0199 as a Novel Respiratory Stimulant Read More »

Distinguished Counsel and FDA Regulatory Scholar Will Lend His Expertise on Corporate and Strategic Matters His extensive experience and knowledge of life sciences, including expertise around opioids in our healthcare system, will be real assets as we pioneer a new approach to the opioid crisis.” — David Kalergis, CEO of Atelerix Life Sciences Inc.CHARLOTTESVILLE, VA, …

Peter Barton Hutt Joins Atelerix Life Sciences Board of Directors Read More »

CHARLOTTESVILLE, VA, UNITED STATES, September 14, 2021 /EINPresswire.com/ — Atelerix Life Sciences Inc., a leader in new therapeutics for unmet medical needs related to opioid use, today announced the appointment of James Bates, MD, PhD, to the position of Chief Medical Officer, where he will oversee the Company’s drug development initiatives. Dr. Bates comes to …

Atelerix Life Sciences Appoints James Bates as CMO Read More »

Novel small molecule technology reverses life-threatening opioid-induced respiratory depression without diminishing pain relief Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Virginia-based biotechnology company, have signed a two-year option to license a novel family of small molecules called Active Thiol-Based Compounds (ATBCs) to prevent or reverse life-threatening opioid-related side effects. CLICK TO …

Case Western Reserve and Atelerix Life Sciences Inc. sign option license to develop new therapeutic approach to opioid crisis Read More »